Growth Hormone Research · Peptide Comparisons

Ipamorelin vs GHRP-2: Selectivity, GH Pulse Profiles, and Research Protocol Differences

Topics covered: Receptor pharmacology comparison · GH pulse amplitude and selectivity · Cortisol and prolactin co-secretion · Protocol design for each compound · Which GHRP for which research objective

Ipamorelin and GHRP-2 (Growth Hormone Releasing Peptide-2) are both synthetic agonists of the ghrelin receptor (GHS-R1a) — the primary receptor mediating growth hormone secretion in response to ghrelin and its synthetic analogues. Despite sharing the same primary receptor target, these two compounds have meaningfully different pharmacological profiles that make them suited to different research applications. The key distinction is selectivity: Ipamorelin is highly selective for GH secretion, while GHRP-2 produces a broader hormonal response that includes co-secretion of cortisol and prolactin.

This distinction is not merely academic — it has direct implications for experimental design. A study using GHRP-2 to investigate GH-dependent effects on muscle protein synthesis must account for the confounding effects of cortisol co-secretion, which has catabolic effects on muscle tissue that partially oppose the anabolic effects of GH. A study using Ipamorelin does not face this confound. Conversely, a study investigating the role of ghrelin receptor activation in cortisol regulation may specifically require GHRP-2’s broader hormonal profile.

1. Receptor Pharmacology: GHS-R1a Agonism and Selectivity

Both Ipamorelin and GHRP-2 are synthetic peptide agonists of the growth hormone secretagogue receptor type 1a (GHS-R1a), the receptor for endogenous ghrelin. GHS-R1a is expressed predominantly in the pituitary gland (where it mediates GH release) and the hypothalamus (where it modulates feeding behaviour and energy homeostasis), but is also found in peripheral tissues including the heart, liver, and adipose tissue.

The selectivity difference between Ipamorelin and GHRP-2 arises from their different binding characteristics at GHS-R1a and at secondary receptor targets. GHRP-2 is a first-generation GHRP with broader receptor interactions that include activation of pathways leading to ACTH (adrenocorticotropic hormone) and prolactin secretion in addition to GH. Ipamorelin was specifically designed to be a more selective GHS-R1a agonist — its structure was optimised to retain GH-stimulating potency while minimising off-target hormonal effects.

At the molecular level, Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) with a molecular weight of 711.9 Da. GHRP-2 is also a hexapeptide (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂) with a molecular weight of 817.9 Da. Both have similar plasma half-lives of approximately 2 hours, making them pharmacokinetically comparable — the key differences are pharmacodynamic, not pharmacokinetic.

2. GH Pulse Profiles: Amplitude, Duration, and Frequency

GHRP-2 generally produces a larger peak GH response than Ipamorelin at equivalent molar doses in rodent studies. This is partly because GHRP-2’s broader receptor interactions include activation of pathways that amplify the GH secretory response beyond what GHS-R1a activation alone produces. The trade-off is that this larger GH pulse comes with co-secretion of cortisol and prolactin.

Ipamorelin produces a GH pulse that is somewhat smaller in amplitude than GHRP-2 at equivalent doses, but the pulse is highly specific to GH — cortisol and prolactin remain essentially unchanged. When Ipamorelin is co-administered with a GHRH analogue (CJC-1295 without DAC or Sermorelin), the synergistic effect produces a GH pulse that is comparable in amplitude to GHRP-2 alone, but without the cortisol and prolactin co-secretion.

Both compounds produce GH pulses with similar kinetics in the published rodent studies: a peak within the first half-hour and a return to baseline within two to three hours, which is why both appear in pulsatile-profile study designs.

3. Cortisol and Prolactin Co-Secretion: The Key Selectivity Difference

The cortisol co-secretion associated with GHRP-2 administration is the most important pharmacological distinction between the two compounds from a research design perspective. Cortisol is a glucocorticoid with broad metabolic effects including: gluconeogenesis, protein catabolism in skeletal muscle, lipolysis in adipose tissue, immunosuppression, and anti-inflammatory activity. In studies examining GH-dependent anabolic effects, cortisol co-secretion introduces a confounding catabolic signal that can mask, attenuate, or complicate the interpretation of GH-mediated effects.

The magnitude of GHRP-2-induced cortisol elevation is reported as concentration-dependent in the rodent literature: small at the low end of the ranges studied and pronounced at the exposures that produce robust GH pulses, which is why the published designs treat cortisol as a co-primary endpoint.

Prolactin co-secretion with GHRP-2 is generally less pronounced than cortisol co-secretion and may be less relevant for most research applications. However, in studies examining reproductive physiology, lactation, or prolactin-dependent signalling pathways, GHRP-2-induced prolactin elevation is a significant confounder.

Ipamorelin does not produce significant cortisol or prolactin co-secretion at research doses. This selectivity makes Ipamorelin the preferred GHRP for studies where GH-specific effects need to be isolated from the broader hormonal effects of ghrelin receptor activation.

4. Head-to-Head Pharmacological Comparison

5. Where the Literature Uses Each GHRP

Ipamorelin in the Literature

• GH-specific effects need to be isolated: Studies examining GH-dependent anabolic effects on muscle, bone, or connective tissue where cortisol co-secretion would confound results.
• Combination with GHRH analogues: The Ipamorelin/CJC-1295 (Mod GRF 1-29) combination is the most studied and best-characterised pulsatile GH stimulation pairing in preclinical research.
• Chronic studies: Ipamorelin’s selectivity profile is the reason it appears in chronic designs where cumulative cortisol exposure would confound metabolic endpoints.
• Studies in metabolically sensitive models: Diabetic, obese, or sarcopenic animal models where cortisol co-secretion would exacerbate metabolic dysfunction.

GHRP-2 in the Literature

• Studies designed around GH pulse amplitude: Designs built on the largest GH pulse, where cortisol co-secretion is not a confound for the endpoints measured.
• Studying GHS-R1a-mediated cortisol regulation: Research specifically examining the interaction between ghrelin receptor activation and the HPA axis.
• Appetite and feeding behaviour studies: GHRP-2’s orexigenic effects (mediated through hypothalamic GHS-R1a) are the reason it appears in studies of feeding behaviour and energy homeostasis.
• Cardioprotective mechanism studies: GHRP-2 has been studied for cardioprotective effects that may involve mechanisms beyond GH secretion, including direct GHS-R1a activation in cardiac tissue.

6. Kinetics and Measurement Endpoints

Both compounds have similar pharmacokinetic profiles in the pre-clinical literature (plasma half-life in the order of two hours). The published studies describe a GH peak within the first half-hour after exposure and a return to baseline within two to three hours, which is why their GH endpoints are reported as pulse amplitude and area under the curve rather than as a steady level, and why IGF-1 is read as an integral over repeated pulses.

Where GHRP-2 is used, the literature reports cortisol alongside GH, because the two rise together and GH-dependent endpoints are otherwise uninterpretable. Receptor desensitisation with repeated exposure is reported for both compounds and is a stated limitation of chronic designs.

These are descriptions of what the literature measures and why. This guide gives no doses, volumes, routes, schedules or sampling times, and none should be inferred from it; laboratory reconstitution and storage are covered in the handling and storage guides.

7. Combination Studies with GHRH Analogues

The combination of a GHRP (Ipamorelin or GHRP-2) with a GHRH analogue (CJC-1295 without DAC, Sermorelin) produces synergistic GH release that is significantly greater than either compound alone. This synergy is well-documented in the preclinical literature and is the basis for the widespread use of GHRP/GHRH combination designs in GH research.

The synergistic mechanism involves the convergence of two distinct intracellular signalling pathways: GHRH receptor activation increases intracellular cAMP (via Gs protein coupling), while GHS-R1a activation increases intracellular calcium and activates PKC (via Gq protein coupling). Both pathways contribute to GH secretory granule exocytosis, and their co-activation produces a supra-additive response.

In the combination literature Ipamorelin is the more common GHRP component, because Ipamorelin with CJC-1295 (Mod GRF 1-29) produces a large, selective GH pulse without the cortisol and prolactin co-secretion reported for GHRP-2. The Core Research catalogue lists the two peptides as a single co-lyophilised preparation.

Related Guides & Resources